Metastatic Hormone –Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy

Opinion StatementTreatment for metastatic hormone –sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual p atient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals o f cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research